Key result
The provided text contains only website navigation boilerplate, so no findings regarding telmisartan and walking performance in peripheral artery disease could be extracted.
Answers are grounded in this paper and cite their sources.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Bonaca et al. (2022) studied Peripheral Artery Disease. Telmisartan was evaluated. The provided text contains only website navigation boilerplate, so no findings regarding telmisartan and walking performance in peripheral artery disease could be extracted.
Synapse has enriched 10 related papers. Consider them for comparative context: